Background Before considering whether to use a multivariable (diagnostic or prognostic)
prediction model, it is essential that its performance be evaluated in data that were not used …

Advances in our understanding of the role of magnetic resonance imaging (MRI) for the
detection of prostate cancer have enabled its integration into clinical routines in the past two …

After developing a prognostic model, it is essential to evaluate the performance of the model
in samples independent from those used to develop the model, which is often referred to as …

For modern evidence‐based medicine, a well thought‐out risk scoring system for predicting
the occurrence of a clinical event plays an important role in selecting prevention and …

Background Optimum management of clinically localised prostate cancer presents unique
challenges because of the highly variable and often indolent natural history of the disease …

Abstract Background The Onco type DX® Prostate Cancer Assay is a multi-gene RT-PCR
expression assay that was developed for use with fixed paraffin-embedded (FPE) diagnostic …

BACKGROUND: The authors previously developed and validated the Cancer of the Prostate
Risk Assessment (CAPRA) score to predict prostate cancer recurrence based on …

Localized prostate cancer shows great clinical, genetic and environmental heterogeneity;
however, prostate cancer treatment is currently guided solely by clinical staging, serum PSA …

More than 1,000,000 men undergo prostate biopsy each year in the United States, most for
“elevated” serum prostate-specific antigen (PSA). Given the lack of specificity and unclear …

Despite the extensive development of prostate cancer (PCa) risk models that are used for
patient–clinician decision-making for PCa screening, their predictive accuracy is unknown …